Jun 2026 (Q2 FY26) — Aug 6, 2026
ICU Medical Q2 FY26 — Strong Organic Growth and Raised Full-Year Guidance
Read the full callICU Medical (ICUI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
ICU Medical earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 552 | +0.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 7.1 | +5.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 19.1 | −46.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$167.23 +2.79% · +$4.54
Performance +42.6% 1Y
1Y: $117.31 on 14 Oct 2025 → $167.23. High $187.26 (19 Aug 2026), low $115.45 (29 Apr 2026).
- Previous close
- $162.69
- 52-week range
- $115.45 – $187.26
- One year
- +43.80%
Overview
- Symbol
- ICUI
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
ICU Medical Q1 FY26 — Strong Infusion Systems Growth and Gross Margin Expansion
Read the full callEvery analysed call
ICU Medical earnings calls (ICUI)
Financials
What the filings say
Net profit, year on year: −46% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 589 | 630 | 605 | 549 | 537 | 541 | 530 | 552 |
| Operating profit | 8 | 38 | 13 | 11 | 14 | 6 | 14 | 39 |
| Operating margin | 1.4% | 6.0% | 2.1% | 1.9% | 2.5% | 1.0% | 2.6% | 7.1% |
| Other income | -1 | -6 | -2 | 2 | 1 | -1 | -1 | -0 |
| Interest | 25 | 34 | 22 | 21 | 20 | 31 | 16 | 16 |
| Profit before tax | -18 | 8 | -11 | 34 | -3 | -16 | -4 | 23 |
| Tax rate | −84.0% | 390.0% | −41.9% | 3.5% | 26.2% | 16.7% | 873.3% | 30.6% |
| Net profit | -33 | -24 | -15 | 35 | -3 | -16 | 30 | 19 |
| EPS ($ per share) | -1.35 | — | -0.63 | 1.43 | -0.14 | — | 1.22 | 0.76 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | 621 | 722 | 809 | 912 | 838 | 808 | 690 | 691 |
| Total liabilities | 322 | 315 | 261 | 265 | 2,426 | 2,255 | 2,239 | 1,927 |
| Fixed assets | 433 | 456 | 467 | 468 | 636 | 613 | 443 | 452 |
| Total assets | 1,585 | 1,692 | 1,764 | 1,881 | 4,516 | 4,378 | 4,204 | 4,051 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 160 | 102 | 223 | 268 | -62 | 166 | 204 | 180 |
| Cash from investing | -103 | -167 | -98 | -91 | -1,909 | -88 | -89 | 122 |
| Cash from financing | 8 | -11 | -0 | -17 | 1,637 | -36 | -56 | -312 |
| Net cash flow | 55 | -76 | 127 | 157 | -344 | 45 | 54 | -1 |
| Capital expenditure | -93 | -97 | -92 | -69 | -90 | -84 | -79 | -88 |
| Free cash flow | 67 | 5 | 131 | 199 | -152 | 82 | 125 | 92 |
ICUI operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Capital expenditures General maintenance and capacity expansion at our facilities as well as placement of revenue-generating infusion pumps with customers outside the US | $11MDuring the quarter, we invested $9 million of cash spend for quality system and product-related remediation activities, $17 million on restructuring and integration and $11 million on CapEx for general maintenance and capacity expansion at our facilities as well as placement of revenue-generating infusion pumps with customers outside the USSource: earnings call transcript | $19MDuring the quarter, we invested $11 million of cash spend for quality system and product-related remediation activities, $11 million on restructuring and integration and $19 million on CapEx for general maintenance and capacity expansion at our facilities as well as placement of revenue-generating infusion pumps with customers outside the USSource: earnings call transcript | +72.7% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
78 filings between Nov 11, 2025 and Sep 3, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$8.27M
19 sales by 7 insiders
47% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 33
- Option exercise — converted options into shares
- 25
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 other.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Bonnell Brian Michael | — | $2.72M | Sep 1, 2026 |
| Woolson Daniel | — | $1.70M | Aug 13, 2026 |
| Voigtlander Christian B. | — | $1.63M | Aug 11, 2026 |
| Sanzone Virginia Ruth | — | $1.26M | Sep 3, 2026 |
| Sousa Ben | — | $401.2K | Aug 12, 2026 |
| Greenberg David C. | — | $297.9K | May 12, 2026 |
| FINNEY ELISHA W | — | $249.4K | Aug 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Sanzone Virginia Ruth VP, General Counsel | Sale 10b5-1 plan | 724 | $122.7K |
| Sep 3, 2026 | Sanzone Virginia Ruth VP, General Counsel | Sale 10b5-1 plan | 1,238 | $208.5K |
| Sep 3, 2026 | Sanzone Virginia Ruth VP, General Counsel | Sale 10b5-1 plan | 2,202 | $369.2K |
| Sep 3, 2026 | Sanzone Virginia Ruth VP, General Counsel | Sale 10b5-1 plan | 692 | $118.7K |
| Sep 1, 2026 | Bonnell Brian Michael Chief Financial Officer | Sale 10b5-1 plan | 6,381 | $1.12M |
| Aug 31, 2026 | Bonnell Brian Michael Chief Financial Officer | Sale 10b5-1 plan | 1,712 | $292.8K |
| Aug 31, 2026 | Bonnell Brian Michael Chief Financial Officer | Sale 10b5-1 plan | 1,914 | $329.4K |
| Aug 31, 2026 | Bonnell Brian Michael Chief Financial Officer | Sale 10b5-1 plan | 4,568 | $792.3K |
| Aug 31, 2026 | Bonnell Brian Michael Chief Financial Officer | Sale 10b5-1 plan | 1,113 | $193.6K |
| Aug 13, 2026 | Woolson Daniel VP, GM-Infusion Capital | Sale | 5,417 | $982.3K |
| Aug 12, 2026 | Sousa Ben Chief Information Officer | Sale | 2,250 | $401.2K |
| Aug 11, 2026 | Voigtlander Christian B. Chief Operating Officer | Sale | 8,929 | $1.63M |
| Aug 11, 2026 | FINNEY ELISHA W Director | Sale | 378 | $69.0K |
| May 22, 2026 | Woolson Daniel President | Sale | 2,123 | $280.7K |
| May 14, 2026 | Sanzone Virginia Ruth VP, General Counsel | Sale | 2,447 | $303.6K |
| May 13, 2026 | Hernandez Laurie Director | Option exercise | 1,254 | $0 |
| May 13, 2026 | Abbey Donald Director | Option exercise | 1,254 | $0 |
| May 13, 2026 | Hoffmeister David F Director | Option exercise | 1,254 | $0 |
| May 13, 2026 | Greenberg David C. Director | Option exercise | 1,254 | $0 |
| May 13, 2026 | KENNEDY KOLLEEN T Director | Option exercise | 1,254 | $0 |
| May 13, 2026 | FINNEY ELISHA W Director | Option exercise | 1,254 | $0 |
| May 12, 2026 | Greenberg David C. Director | Sale | 2,424 | $297.9K |
| May 12, 2026 | Greenberg David C. Director | Option exercise | 2,424 | $245.0K |
| Mar 25, 2026 | Abbey Donald Director | Other | 704 | $0 |
| Mar 15, 2026 | Bonnell Brian Michael Chief Financial Officer | Option exercise | 11,400 | $0 |
| Mar 15, 2026 | Voigtlander Christian B. Chief Operating Officer | Tax withheld | 1,795 | $225.9K |
| Mar 15, 2026 | Voigtlander Christian B. Chief Operating Officer | Option exercise | 3,248 | $0 |
| Mar 15, 2026 | Voigtlander Christian B. Chief Operating Officer | Tax withheld | 6,301 | $793.0K |
| Mar 15, 2026 | Voigtlander Christian B. Chief Operating Officer | Option exercise | 11,400 | $0 |
| Mar 15, 2026 | Bonnell Brian Michael Chief Financial Officer | Tax withheld | 5,800 | $729.9K |
| Mar 15, 2026 | Woolson Daniel VP, GM-Infusion Capital | Option exercise | 2,924 | $0 |
| Mar 15, 2026 | Woolson Daniel VP, GM-Infusion Capital | Tax withheld | 1,295 | $163.0K |
| Mar 15, 2026 | Sanzone Virginia Ruth VP, General Counsel | Tax withheld | 897 | $112.9K |
| Mar 15, 2026 | Sanzone Virginia Ruth VP, General Counsel | Option exercise | 1,624 | $0 |
| Mar 15, 2026 | Sanzone Virginia Ruth VP, General Counsel | Tax withheld | 3,150 | $396.4K |
| Mar 15, 2026 | Sanzone Virginia Ruth VP, General Counsel | Option exercise | 5,700 | $0 |
| Mar 15, 2026 | Jain Vivek Chairman and CEO | Tax withheld | 9,452 | $1.19M |
| Mar 15, 2026 | Jain Vivek Chairman and CEO | Option exercise | 17,100 | $0 |
| Mar 15, 2026 | Jain Vivek Chairman and CEO | Tax withheld | 2,693 | $338.9K |
| Mar 15, 2026 | Jain Vivek Chairman and CEO | Option exercise | 4,872 | $0 |
| Mar 15, 2026 | Sousa Ben Chief Information Officer | Tax withheld | 718 | $90.4K |
| Mar 15, 2026 | Sousa Ben Chief Information Officer | Option exercise | 1,300 | $0 |
| Mar 15, 2026 | Bonnell Brian Michael Chief Financial Officer | Tax withheld | 1,795 | $225.9K |
| Mar 15, 2026 | Bonnell Brian Michael Chief Financial Officer | Option exercise | 3,248 | $0 |
| Mar 8, 2026 | Woolson Daniel VP, GM-Infusion Capital | Option exercise | 16,147 | $0 |
| Mar 8, 2026 | Bonnell Brian Michael Chief Financial Officer | Option exercise | 71,757 | $0 |
| Mar 8, 2026 | Bonnell Brian Michael Chief Financial Officer | Tax withheld | 39,667 | $5.24M |
| Mar 8, 2026 | Sanzone Virginia Ruth VP, General Counsel | Tax withheld | 1,762 | $232.6K |
| Mar 8, 2026 | Sanzone Virginia Ruth VP, General Counsel | Option exercise | 3,189 | $0 |
| Mar 8, 2026 | Sanzone Virginia Ruth VP, General Counsel | Tax withheld | 13,221 | $1.75M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ICU MEDICAL INC/DE
Free account. Everything above stays public.
Write why you follow ICU MEDICAL INC/DE and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading